Bactiguard Holding Ab · OMXSTO:BACTI_B
Bactiguard Holding Ab — Pareto Securities' Healthcare Conference 2021
27 slides from Bactiguard Holding Ab's conference presentation, Sep 2, 2021
Slide 1: Pareto Securities' Healthcare Conference 2021
Pareto Securities’ Healthcare Conference 2021 2 September, 2021 Cecilia Edström, CEO
Slide 2: Bactiguard at a glance – setting new standards of care for infection prevention
Bactiguard at a glance – setting new standards of care for infection prevention License Unique technology for Partnering with global agreements and infection prevention market leaders proprietary product portfolio Global coverage Listed on Nasdaq direct or via partners Stockholm, Mid Cap segment ~6.
Slide 3: Hospital acquired infections
Hospital acquired infections European market data Hospital acquired infections 3.2 million cases1 16 million extra hospital days2 Annual HAI related cost of hospital stays 7 billion Euro2 65% of HAI cases related to biofilm 30% infection rate in orthopedic trauma 80% in open fracture cases 3,4,5 1.
Slide 4: The Bactiguard technology
The Bactiguard® technology Effective, safe and well protected • Coating of noble metals Gold Au • Galvanic effect when in contact with fluids Silver Ag Palladium Pd • Prevents microbial adhesion (gram positive/negative bacteria and fungi) • Non-releasing and long lasting • Effective and safe • Stron
Slide 5: Product portfolio and business model
Product portfolio and business model Addressing need for infection prevention and generating synergies 5
Slide 6: Continuously strengthening clinical evidence
Continuously strengthening clinical evidence Competitive advantage and barrier to entry • >200 million Bactiguard coated catheters used • No reported adverse events associated with the coating • Over 40 clinical studies including more than 100,000 patients • 42% weighted average reduction of symptom
Slide 7: Recent developments
Recent developments 7
Slide 8: Financial developments
Financial developments COVID-19 continues to impact the business • Stable recurring BD license revenues • License revenues from Zimmer Biomet will increase gradually • Growing BIP revenues • New products added and new partnerships established • New license revenues driven by new agreements – ambitio
Slide 9: Looking ahead
Looking ahead 9
Slide 10: Strategic focus and value creation
Strategic focus and value creation LICENSE • Roll out of ZNN Bactiguard in EMEA, next step US and RoW BUSINESS • Multi-center clinical trials in long term applications - KOL network • Expanding into new applications – several interesting dialogues ongoing • Strengthening the team BACTIGUARD • Expand
Slide 11: Zimmer Biomet EMEA launch
Zimmer Biomet EMEA launch Positioning of Bactiguard technology
Slide 12: Bactiguard coating a game changer
Bactiguard coating a game changer The C.R Bard (BD) experience Unit sales thousands 12000 10000 • Limited clinical evidence at launch - Bard introduced risk sharing model and 8000 ”money back guarantee” to kick-start sales 6000 • Strong volume growth over 15 years 4000 (~40% market share), thereafte
Slide 13: Major potential for growth in new applications
Major potential for growth in new applications Global market 2017 USD million 13
Slide 14: Bactiguard infection prevention – New standard of care
Bactiguard infection prevention – New standard of care Ten reasons to invest in Bactiguard Long-term owners and 10 1 Contribution to the UN’s Global dedicated management Sustainable Development Goal. 2 Bactiguard’s Profitable growth 9 technology is effective and safe Infection prevention a central c
Slide 15: Prevention is better than cure
Prevention is better than cure 15
Slide 16: Questions & Answers
Questions & Answers Cecilia Edström Gabriella Björknert Caracciolo CEO CFO +46 8 440 58 80 +46 8 440 58 80 cecilia.edstrom@bactiguard.com gabriella.caracciolo@bactiguard.com 16
Slide 17: Upcoming events and financial reports
Upcoming events and financial reports October 28, 2021 • Q3, 2021 17
Slide 18: Back-up
Back-up 18
Slide 19: Bactiguard's vision
Bactiguard’s vision Establish a new standard of care for infection prevention Save lives Reduce cost Reduce the use of antibiotics Prevent the spread of multi resistant bacteria 19
Slide 20: A Swedish history of Innovation
Bactiguard A Swedish history of Innovation 1994 1995 1978 FDA 510k Patent in the US Billy Södervall 2008 starts developing Launch of the Bactiguard BIP Foley technology 2013 Launch of 1990 2005 BIP CVC & BIP ETT Partnership with Bactiguard AB C.R. Bard founded 2014 Share listed on Nasdaq, Stockholm
Slide 21: Executive Management Team
Executive Management Team Cecilia Edström, CEO Stefan Grass, Chief Medcial Officer (CMO) Gabriella Björknert Caracciolo, CFO Peter Rådqvist, Gobal Head of Sales Sathish Subramaniam, COO Petra Kaur Ljungman, CMCO Carl Johan Fredin, Chief Licensing Officer 21
Slide 22: Experienced Board of Directors
Experienced Board of Directors Thomas von Koch Christian Kinch Prof Anna Martling Jan Ståhlberg Cecilia Edström Chairman Deputy Chairman Co-founder and Co-founder and Dean Campus North and Founder and CEO of CEO of Bactiguard major shareholder major shareholder Research Group Leader, Trill Impact AB
Slide 23: Shareholder base
Shareholder base Share of capital CHRISTIAN KINCH WITH FAMILY AND % OF COMPANY; 18,3% SHAREHOLDERS CAPITAL % OF VOTES OTHERS; 27,8% Christian Kinch with family 18,3 % 34,7 % and company Thomas von Koch and 18,3 % 34,7 % company THOMAS VON Nordea Investment Funds 10,2 % 4,9 % KOCH AND COMPANY; 18,3%
Slide 24: Acquisition paving the way for business development
Acquisition paving the way for business development 2021 Sept 2021 June Bactiguard wound 2020 February ZNN Bactiguard care launch D and ES Bactiguard acquires Vigilenz 2021 Jan EMEA launch Aniocyn ZNN Bactiguard Nordic launch Bactiguard Wound CE mark Care launch Sweden 2020 March Hydrocyn disinfecti
Slide 25: Developing a hybrid distribution model
Developing a hybrid distribution model • Developing our distribution Customer / Patient model • Broader product portfolio for infection prevention • Capitalise on the increasing Own sales force Distributor Bactiguard / Distributor need for infection Service Specialists prevention Demand Physical Aft
Slide 26: Expanding portfolio for infection prevention
Expanding portfolio for infection prevention Hypochlorous acid DISINFECTION HYDROCYN WOUND CARE VIGILENZ B2B HYDROCYN BACTIGUARD WOUND CARE WOUND CARE ANIOCYN VETERINARY CARE 26
Slide 27: Business highlights - second quarter 2021
Business highlights - second quarter 2021 Major breakthrough with Zimmer Biomet and new partnerships for wound care LICENSE BUSINESS BACTIGUARD PORTFOLIO • CE-mark for orthopaedic trauma • New partnerships for Bactiguard implants from Zimmer Biomet in Wound Care: January, production start in April •
Bactiguard — Pareto Securities' Healthcare Conference 2021 on 6ix